These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
675 related items for PubMed ID: 16409282
1. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Moosavi Z, Nakhli A, Rassaii S. Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282 [No Abstract] [Full Text] [Related]
2. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B, Abbaszadeh B, Khamesipour A. Eur J Dermatol; 2005 Dec; 15(2):85-7. PubMed ID: 15757817 [Abstract] [Full Text] [Related]
3. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Salmanpour R, Razmavar MR, Abtahi N. Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529 [No Abstract] [Full Text] [Related]
4. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Faghihi G, Tavakoli-kia R. Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620 [Abstract] [Full Text] [Related]
5. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R. Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664 [Abstract] [Full Text] [Related]
10. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A. J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991 [Abstract] [Full Text] [Related]
11. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655 [Abstract] [Full Text] [Related]
12. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Bogenrieder T, Lehn N, Landthaler M, Stolz W. Dermatology; 2003 Dec; 206(3):269-72. PubMed ID: 12673089 [Abstract] [Full Text] [Related]
13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD. Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547 [Abstract] [Full Text] [Related]
14. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013 [Abstract] [Full Text] [Related]
15. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Sadeghian G, Nilfroushzadeh MA, Iraji F. Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205 [Abstract] [Full Text] [Related]
16. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T. Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637 [Abstract] [Full Text] [Related]
17. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis. Solomon M, Ollech A, Pavlotsky F, Barzilai A, Schwartz E, Baum S, Astman N. Acta Derm Venereol; 2024 Apr 29; 104():adv35089. PubMed ID: 38682801 [Abstract] [Full Text] [Related]
18. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ. Am J Trop Med Hyg; 2007 Oct 29; 77(4):640-6. PubMed ID: 17978064 [Abstract] [Full Text] [Related]
19. In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study. Gutiérrez J, Vallejo B, Barbosa H, Pinzón J, Delgado G. Immunopharmacol Immunotoxicol; 2013 Jun 29; 35(3):321-8. PubMed ID: 23473403 [Abstract] [Full Text] [Related]
20. Allopurinol in the treatment of American cutaneous leishmaniasis. Martinez S, Marr JJ. N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379 [Abstract] [Full Text] [Related] Page: [Next] [New Search]